| abstract |
Methods are disclosed to reduce apolipoprotein C-III (apoC-III) mRNA or protein in a subject in need thereof, comprising administering a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein R 1 and R 2 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C 1 -C 6 alkyl groups, with the proviso that R 1 and R 2 are not both hydrogen. |